Guardant Resolves Pending Litigation With Illumina; Enters Into New Agreement To Advance Long-Term Commercial Partnership And Cancer Research
Portfolio Pulse from Benzinga Newsdesk
Guardant Health (GH) has resolved its pending litigation with Illumina (ILMN) and entered into a new agreement to advance their long-term commercial partnership and cancer research. The details of the agreement were not disclosed.
August 04, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health has resolved its litigation with Illumina and entered into a new partnership agreement. This could potentially boost its long-term prospects in cancer research.
The resolution of the litigation removes a potential risk for Guardant Health, and the new partnership agreement could provide opportunities for growth in the field of cancer research.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Illumina has resolved its litigation with Guardant Health and entered into a new partnership agreement. This could potentially boost its long-term prospects in cancer research.
The resolution of the litigation removes a potential risk for Illumina, and the new partnership agreement could provide opportunities for growth in the field of cancer research.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100